Antimicrobial compounds, compositions, and uses thereof
Inventors
Sleet, Randolph B. • Kates, Steven A. • Parkinson, Steven
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Antimicrobial compounds and compositions of Formula (I) and methods of use are disclosed.
Core Innovation
The disclosed subject matter concerns antimicrobial compounds having Formula (I) (Nu-8/Compound (I)) and pharmaceutically acceptable salts of the compounds. The disclosure includes specific salts including sodium, ammonium, calcium, potassium, magnesium, and cobalt salts, and also includes protonated forms of the compound as a function of aqueous pH.
The disclosure states that biological activity is higher above pH ~3 and includes protonated compound forms in aqueous pH 3-5. The disclosure further describes pharmaceutical compositions comprising the antimicrobial compound or a pharmaceutically acceptable salt thereof and indicates that the compounds can be formulated for multiple routes of administration.
The disclosure describes administration routes including topical administration, oral administration, inhalation administration, intravesical administration via catheter, and parenteral administration. It also includes treatment indications for multiple infection types, including diabetic foot ulcer infection, complicated catheter-associated UTI, cystic-fibrosis lung infection, ventilator-associated pneumonia, burn wound infection, otitis externa, bacterial vaginosis, and impetigo.
Claims Coverage
The independent claim coverage includes a method of treating a bladder infection by administering an effective amount of a compound having a specified formula, or a pharmaceutically acceptable salt. The inventive features are further narrowed by dependent claims across infection subtype, delivery, dosage ranges, and specific salt identification.
Treating a bladder infection with Formula (I) compound or pharmaceutically acceptable salt
A method of treating a bladder infection in a patient in need thereof, comprising administering to the patient an effective amount of a compound having the formula, or a pharmaceutically acceptable salt thereof.
Treating a urinary tract bladder infection
The method is limited to treating a bladder infection that is a urinary tract infection.
Treating a catheter-associated complicated urinary tract infection
The complicated urinary tract infection is a catheter-associated urinary tract infection.
Administering the compound through a catheter
The compound or a pharmaceutically acceptable salt is administered through a catheter.
Dose expressed as mg per kg of patient body weight
The administered amount of the compound or its pharmaceutically acceptable salt is between about 0.1 mg and about 1000 mg per kilogram of patient body weight.
Specific sodium salt species
The administered compound is the sodium salt identified as sodium ((2R,3S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-((butoxyoxidophosphor-yl)oxy)tetrahydrofuran-2-yl)methyl butyl phosphate.
Across the independent method claim and its dependents, the core coverage is a bladder-infection treatment using Formula (I) (Nu-8/Compound (I)) or a pharmaceutically acceptable salt, with further limitation to urinary tract and catheter-associated complicated forms, catheter-based delivery, expressed dosing, and an example of a specific sodium salt species.
Stated Advantages
Demonstrated strong antimicrobial killing under clinically relevant acidic pH.
Demonstrated efficacy in infection models.
Documented Applications
Treatment of diabetic foot ulcer infection.
Treatment of complicated catheter-associated urinary tract infection (catheter-associated UTI).
Treatment of cystic-fibrosis lung infection.
Treatment of ventilator-associated pneumonia (ventilator acquired pneumonia).
Treatment of burn wound infection.
Treatment of otitis externa.
Treatment of bacterial vaginosis.
Treatment of impetigo.
Treatment of human complicated urinary tract infection, including intravesical catheter administration.
Nebulizer inhalation for infection scenarios described in the document.
Topical gel administration for infection scenarios described in the document.
Infection model support for Nu-8 and Nu-8 sodium salt via in vivo/in vitro antimicrobial efficacy and cytological profiling.
Interested in licensing this patent?